JPRN-jRCT2031230263招募中2 期
Phase 2 platform study evaluating combination therapy with TAS-116 (pimitespib) in patients with malignant tumors - CHAPTER-Platform-201
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Sato Atsushi
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Castration-resistant prostate cancer (CRPC) cohort
- •- Provided written informed consent
- •- Histologically confirmed prostatic cancer
- •- Had the treatment with novel hormone agent (NHA) as the most recent previous treatment
- •- CRPC or metastatic hormone-sensitive prostate cancer previously treated with one NHA
- •- Documented disease progression during treatment with NHA as the most recent therapy
- •- Naive to chemotherapy (cytotoxic anticancer drugs, etc) and Ra-223 as treatment for metastatic CRPC
- •- Have at least one evaluable lesion per RECIST v1.1 and/or bone metastatic disease detected by bone scintigraphy
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
排除标准
- •CRPC cohort
- •- A serious illness or medical condition
- •- Previous or concurrent cancer that is distinct in primary disease or histology from cancer that is being evaluated in this study
- •- QTcF interval >470 msec at baseline
研究者
相似试验
进行中（未招募）
不适用
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.EUCTR2014-001620-29-ESGrupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)77
已完成
不适用
A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients wit relapsed or rogressive Waldenström’s macroglobiulinemia. A HOVON / Greek Myeloma Study Group studyWaldenström’s macroglobulinemia (WM)NL-OMON27880Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center-CTCErasmus MC P.O. box 2040NL- 3000 CA RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl72
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread and has not responded to a course of anti-cancer treatment and a study in HER2-positive gastric cancer that has spread and has not been treated with any chemotherapeutic agent before.Her2 postive metastatic breast cancer and Her2 positive locally advanced or metastatic gastric cancer.MedDRA version: 14.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001547-46-ESF. Hoffmann-La Roche Ltd146
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread and has not responded to a course of anti-cancer treatment and a study in HER2-positive gastric cancer that has spread and has not been treated with any chemotherapeutic agent before.EUCTR2012-001547-46-FRF. Hoffmann-La Roche Ltd146
进行中（未招募）
不适用
This is a trial for women with metastatic breast cancer that test positive for a biological protein called Her 2 and a biological enzyme called Topoisomerase II alpha.Patients will receive Epirubicin and Lapatinib.Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.MedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005002-30-IEICORG-the All Ireland co-operative Oncology Research group46